Latest Iontophoresis Stories
Innovative technologies by SESHA Skin Therapy, BIOBLISS and RG-Cell fFocus on skin penetration to increase efficacy of anti-aging products. New York, NY (PRWEB)
Scientists have confirmed the feasibility of using a new drug delivery system â€” the basis for a battery-powered skin patch â€” to administer medication that shows promise for treating peripheral artery disease (PAD) and healing stubborn skin ulcers and burns.
QUAKERTOWN, Pa., March 22, 2011 /PRNewswire-USNewswire/ -- Spring has sprung, which means summer sweat is not far behind.
Vyteris, Inc. (OTC BB: VYTR), manufacturer of the first U.S.
EyeGate Pharma, a privately held specialty pharmaceutical company using iontophoresis technology to safely and non-invasively deliver therapeutics into the front and back of the eye to treat serious ocular diseases, today announced the initiation of patient dosing in a prospective, multi-center, randomized, double-masked U.S.
Vyteris, Inc. (OTCBB: VYTR), manufacturer of the first FDA-approved active patch transdermal drug delivery system, announced implementation of a 1 for 15 reverse split of the company's common stock, as well as the designation of a new trading symbol by NASDAQ.
ST. PAUL, Minn., Jan. 21 /PRNewswire/ -- For years, physical therapists have relied on iontophoresis as a safe, reliable and effective drug delivery method. At the same time, most PTs have suffered the drawbacks of traditional dose controllers, lead wires and patch-only iontophoresis systems.
- A ceramic container used inside a fuel-fired kiln to protect pots from the flame.